Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 21, 2015


Immune Therapeutics, Inc.

(Exact name of registrant as specified in its charter)




Florida 000-54933 59-3226705
(State or other jurisdiction (Commission (IRS Employer
or incorporation) File Number) Identification Number)



37 North Orange Avenue, Suite 607, Orlando, Florida 32801
(Address of principal executive offices) (Zip Code)



(888) 613 - 8802

(Registrant’s telephone number, including area code)




Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



( 1 )



Item 8.01 Other Events.


ClearTrust, LLC is our new transfer agent and shareholder provider. ClearTrust, LLC acquired all issuer accounts of our former transfer agent, Guardian Registrar & Transfer, Inc. As a result, effective January 21, 2015, ClearTrust, LLC became our transfer agent. All of the directly held shares of common stock of our shareholders were transferred from Guardian Registrar & Transfer, Inc. to ClearTrust, LLC’s platform. A copy of the letter to our shareholders regarding this change is attached hereto as Exhibit 99.1 and incorporated herein by reference.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits



  Exhibit No. Description
  99.1 Shareholder Letter Regarding Transfer Agent Change



( 2 )






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




    Immune Therapeutics, Inc.
    By: /s/ Noreen Griffin
    Noreen Griffin, Chief Executive Officer




Date: January 26, 2015





  Exhibit No. Description
  99.1 Shareholder Letter Regarding Transfer Agent Change









Exhibit 99.1


January 26, 2015


ClearTrust, LLC is Immune Therapeutics’

New Transfer Agent and Support Provider


No Action Required of Shareholders for this Transaction




Dear Immune Therapeutics, Inc. Shareholder:


I am writing today to update you on an important operational change. ClearTrust, LLC, a leading stock transfer agent serving growth companies and community banks, has acquired all issuer accounts of Guardian Registrar & Transfer, Inc., our transfer agent. As a result, ClearTrust is now Immune Therapeutics’ transfer agent and shareholder support provider.


This change includes the transfer of your directly held shares of Immune Therapeutics’ common stock from Guardian Registrar & Transfer to ClearTrust’s platform. There is no action required on your part for this transaction.


If you have any questions regarding your shares, please contact a ClearTrust specialist by telephone at (813) 235-4490 or email at inbox@ClearTrustTransfer.com. If you need to send documents to ClearTrust, such documents can be emailed to the foregoing email address, faxed to (813) 388-4549 or mailed to 16540 Pointe Village Drive, Suite 210, Lutz, Florida 33558.



Thank you for your continued support of Immune Therapeutics.



    Noreen Griffin
    Chief Executive Officer




37 North Orange Ave, Suite 607, Orlando, FL 32801

(888) 613-8802 Fax: (866) 514-8807